Congress of Asian Pacific Society of Respirology (APSR 2024)

Hong Kong 07 November 2024 - 10 November 2024

CPAP still valuable for OSA patients despite absence of CV benefits in RCTs

06 Jan 2025 by

The reasons why continuous positive airway pressure (CPAP) treatment has not been shown to reduce cardiovascular (CV) events in randomized trials on obstructive sleep apnoea (OSA) are multifaceted. However, research still suggests that such patients can benefit from CPAP, according to an evidence review presented at APSR 2024.

CPAP still valuable for OSA patients despite absence of CV benefits in RCTs

06 Jan 2025

GLP1-RAs hold potential for asthma control

12 Dec 2024 by

Data presented at APSR 2024 demonstrate the ability of glucagon-like peptide 1 receptor agonists (GLP1-RAs) to benefit obese individuals with asthma.

GLP1-RAs hold potential for asthma control

12 Dec 2024

BPaLM regimen looks good for drug-resistant TB in children, adults

09 Dec 2024 by

A therapeutic regimen comprising bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) appears to work against drug-resistant tuberculosis (TB) both in paediatric and adult patients, according to two small studies conducted in Indonesia.

BPaLM regimen looks good for drug-resistant TB in children, adults

09 Dec 2024

RSV places strain on HK’s public health system, but vaccination reduces burden

06 Dec 2024 by

Respiratory syncytial virus (RSV)-associated infections in older adults impose a substantial economic burden on Hong Kong’s public health system, but the good news is that this burden may be mitigated by vaccination.

RSV places strain on HK’s public health system, but vaccination reduces burden

06 Dec 2024

Triple therapy improves health status of COPD patients in real-world setting

30 Nov 2024 by

Treatment with budesonide/glycopyrronium/formoterol (BGF), a triple therapy delivered via metered-dose inhaler (MDI), improves health status in Chinese patients with chronic obstructive pulmonary disease (COPD), based on real-world data presented at APSR 2024.

Triple therapy improves health status of COPD patients in real-world setting

30 Nov 2024

BGF inhaler safe to use in COPD patients

25 Nov 2024 by

Treatment with budesonide/glycopyrrolate/formoterol (BGF) using a metered dose inhaler (MDI) demonstrates an acceptable safety profile and improves symptoms in patients with chronic obstructive pulmonary disease (COPD) in a real-world clinical setting, results of the TORES study have shown.

BGF inhaler safe to use in COPD patients

25 Nov 2024